Tokyo, Jan. 7 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060270) titled 'An Open-Label, Single-Arm Phase II Study of Enfortumab Vedotin Plus Pembrolizumab in Patients with Unresectable Urothelial Carcinoma' on Jan. 6.
Study Type:
Interventional
Study Design:
Basic Design - Single arm
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Historical
Primary Sponsor:
Institute - Kanazawa University
Condition:
Condition - Urothelial Carcinoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the efficacy of enfortumab vedotin in combination with pembrolizumab in patients with unresectable urothelial carc...